MDSLD & Met-ALD

Breast Cancer

October 19, 2023

Immunization Update

October 31, 2023

Published by mesn on October 26, 2023

Categories

TRENDING WELLNESS TOPIC: Metabolic Dysfunction-Associated Steatotic Liver Disease and Met-ALD

What is the problem?

MASLD, formerly known as NAFLD, is the most common chronic liver condition in the United States, affecting up to 25% of Americans. Most cases of MASLD are found in people middle age and older. MASLD can harm the liver if its underlying cause isn’t recognized and treated. Metabolic Dysfunction-Associated Steatotic Liver Disease and its progressive form, Met-ALD (formerly NASH) are the most common causes of chronic liver disease in industrialized countries, including liver cirrhosis, hepatocellular carcinoma, and liver failure. It’s estimated that 1.5% – 6.5% of US adults have Met-ALD. The prevalence of MASLD in the United States is increasing owing to a rising incidence of obesity and type 2 diabetes mellitus. Physicians need the most up-to-date tools to diagnose, treat, and manage their adult and pediatric patients’ care since fatty liver is frequently under-recognized in the primary care setting.

Learning Objectives

After this activity, the learners will be able to:

Understand the new terminology to describe patients with Nonalcoholic fatty liver disease

Summarize the healthcare burden unique to patients with MASH and challenges to optimal identification and management

Explain best practices in the identification of patients with MASH and those patients with the highest risk of suboptimal outcomes

Recall the impact of present and emerging pharmacotherapies for MASH on liver fibrosis and hepatocellular inflammation

Formulate a treatment plan for a patient with MASH

CLICK HERE to download a PDF file featuring information gaps, potential needs, and references for this topic.

If your medical staff needs an update on MASLD (fatty liver) and Met-ALD, consider contacting our office to book a speaker at 877-505-4777 or info@speakersnetwork.com.